In the United States, peripheral arterial disease (PAD) affects about 10 million individuals,
and is also prevalent worldwide. Medical therapies for symptomatic relief are limited.
Surgical or endovascular interventions are useful for some individuals, but long-term results
are often disappointing. As a result, there is a need for developing new therapies to treat
PAD. The murine hindlimb ischemia preparation is a model of PAD, and is useful for testing
new therapies. When compared to other models of tissue ischemia such as coronary or …